Cargando…

P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN(®)-multiantigen vaccine: high responder rate and considerable breadth of immunological response

Detalles Bibliográficos
Autores principales:	Overton, T, Schmidt, D, Hain, J, Virgin, G, Steigerwald, R, Dirmeier, U, Jordan, E, Meyer, T, Young, P, Ludvigsen, A, Nichols, R, Chaplin, P
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767928/ http://dx.doi.org/10.1186/1742-4690-6-S3-P411

Ejemplares similares

Immunotherapy with MVA-BN(®)-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells
por: Mandl, Stefanie J., et al.
Publicado: (2011)

LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency
por: Weidenthaler, Heinz, et al.
Publicado: (2022)

LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios
por: Maclennan, Jane, et al.
Publicado: (2019)

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
por: Rollier, Christine S., et al.
Publicado: (2016)

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
por: Greenberg, Richard N., et al.
Publicado: (2016)

Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
por: Chiuppesi, Flavia, et al.
Publicado: (2022)

Asymptomatic Mpox Virus Infection in Subjects Presenting for MVA-BN Vaccine
por: Matusali, Giulia, et al.
Publicado: (2023)

Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants
por: Wussow, Felix, et al.
Publicado: (2023)

Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines
por: Hussein, Waleed M., et al.
Publicado: (2016)

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
por: Zaeck, Luca M., et al.
Publicado: (2022)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults
por: Turner Overton, Edgar, et al.
Publicado: (2023)

An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia
por: Mansour, Ahd A., et al.
Publicado: (2018)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine
por: Jordan, Elke, et al.
Publicado: (2023)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
por: Saubi, Narcís, et al.
Publicado: (2020)

Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer
por: Cecil, Denise L., et al.
Publicado: (2022)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021)

A Novel Naturally Occurring Tandem Promoter in Modified Vaccinia Virus Ankara Drives Very Early Gene Expression and Potent Immune Responses
por: Wennier, Sonia T., et al.
Publicado: (2013)

FtlA and FtlB Are Candidates for Inclusion in a Next-Generation Multiantigen Subunit Vaccine for Lyme Disease
por: Camire, Andrew C., et al.
Publicado: (2022)

Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022
por: Berens-Riha, Nicole, et al.
Publicado: (2022)

Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE(®) against aerosolized rabbitpox virus in a rabbit model()
por: Garza, Nicole L., et al.
Publicado: (2009)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

The Authors Respond
por: Hain, Jocelyn
Publicado: (2010)

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children( )
por: Ishola, D
Publicado: (2022)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Alexandre, Marie, et al.
Publicado: (2023)

Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy
por: Passini, Flavia, et al.
Publicado: (2023)

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
por: Greenberg, Richard N, et al.
Publicado: (2015)

Fusion Expression and Immune Effect of PCV2 Cap Protein Tandem Multiantigen Epitopes with CD154/GM-CSF
por: Mao, Qian, et al.
Publicado: (2021)

The Breadth of Black
Publicado: (1871)

The Breadth of Viruses in Human Semen
por: Salam, Alex P., et al.
Publicado: (2017)

Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
por: Greenberg, Richard N, et al.
Publicado: (2015)

IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality
por: Rodríguez, Ana María, et al.
Publicado: (2012)

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
por: Green, C, et al.
Publicado: (2023)

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B
por: Rosás-Umbert, Miriam, et al.
Publicado: (2017)

A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge
por: Henning, Lisa, et al.
Publicado: (2021)

Breadth in contemporary topology
por: Gay, David T, et al.
Publicado: (2019)

AJRCCM: Strength in Breadth
por: Bush, Andrew, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cok030bpp0020d26f8u9uharq6